280 related articles for article (PubMed ID: 28656509)
1. Older People's Preferences for Side Effects Associated with Antimuscarinic Treatments of Overactive Bladder: A Discrete-Choice Experiment.
Decalf VH; Huion AMJ; Benoit DF; Denys MA; Petrovic M; Everaert KCMM
Drugs Aging; 2017 Aug; 34(8):615-623. PubMed ID: 28656509
[TBL] [Abstract][Full Text] [Related]
2. Patient and physician preferences for oral pharmacotherapy for overactive bladder: two discrete choice experiments.
Heisen M; Baeten SA; Verheggen BG; Stoelzel M; Hakimi Z; Ridder A; van Maanen R; Stolk EA
Curr Med Res Opin; 2016; 32(4):787-96. PubMed ID: 26789823
[TBL] [Abstract][Full Text] [Related]
3. Health Related Quality of Life in Patients with Side-Effects after Antimuscarinic Treatment for Overactive Bladder.
Kim A; Lee KS; Jung R; Na S; Kim JC; Kim HG; Choo MS
Low Urin Tract Symptoms; 2017 Sep; 9(3):171-175. PubMed ID: 27291463
[TBL] [Abstract][Full Text] [Related]
4. Preferences for antimuscarinic therapy for overactive bladder.
Swinburn P; Lloyd A; Ali S; Hashmi N; Newal D; Najib H
BJU Int; 2011 Sep; 108(6):868-73. PubMed ID: 21105989
[TBL] [Abstract][Full Text] [Related]
5. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder.
Yamada S; Ito Y; Nishijima S; Kadekawa K; Sugaya K
Pharmacol Ther; 2018 Sep; 189():130-148. PubMed ID: 29709423
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder.
Andersson KE; Sarawate C; Kahler KH; Stanley EL; Kulkarni AS
BJU Int; 2010 Jul; 106(2):268-74. PubMed ID: 19922546
[TBL] [Abstract][Full Text] [Related]
7. Overactive bladder in the elderly: a guide to pharmacological management.
Staskin DR
Drugs Aging; 2005; 22(12):1013-28. PubMed ID: 16363885
[TBL] [Abstract][Full Text] [Related]
8. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics.
Wagg A; Nitti VW; Kelleher C; Castro-Diaz D; Siddiqui E; Berner T
Curr Med Res Opin; 2016; 32(4):621-38. PubMed ID: 26828974
[TBL] [Abstract][Full Text] [Related]
9. Muscarinic receptor antagonists for overactive bladder.
Abrams P; Andersson KE
BJU Int; 2007 Nov; 100(5):987-1006. PubMed ID: 17922784
[TBL] [Abstract][Full Text] [Related]
10. Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder.
Wagg A; Verdejo C; Molander U
Int J Clin Pract; 2010 Aug; 64(9):1279-86. PubMed ID: 20529135
[TBL] [Abstract][Full Text] [Related]
11. The medical treatment of overactive bladder, including current and future treatments.
Athanasopoulos A; Cruz F
Expert Opin Pharmacother; 2011 May; 12(7):1041-55. PubMed ID: 21299469
[TBL] [Abstract][Full Text] [Related]
12. [Overactive bladder: modulating the effects of antimuscarinic therapy].
Palleschi G; Tubaro A; Miano L
Minerva Urol Nefrol; 2005 Dec; 57(4):237-45. PubMed ID: 16247346
[TBL] [Abstract][Full Text] [Related]
13. A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older.
Wagg A; Arumi D; Herschorn S; Angulo Cuesta J; Haab F; Ntanios F; Carlsson M; Oelke M
Age Ageing; 2017 Jul; 46(4):620-626. PubMed ID: 28057620
[TBL] [Abstract][Full Text] [Related]
14. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly.
Kay GG; Granville LJ
Clin Ther; 2005 Jan; 27(1):127-38; quiz 139-40. PubMed ID: 15763613
[TBL] [Abstract][Full Text] [Related]
15. Effect of Potentially Inappropriate Use of Antimuscarinic Medications on Healthcare Use and Cost in Individuals with Overactive Bladder.
Suehs BT; Davis C; Franks B; Yuran TE; Ng D; Bradt J; Knispel J; Vassilakis M; Berner T
J Am Geriatr Soc; 2016 Apr; 64(4):779-87. PubMed ID: 27059714
[TBL] [Abstract][Full Text] [Related]
16. [Standard pharmacological treatment and new therapies for overactive bladder].
Del Popolo G; Mencarini M; Li Marzi V
Urologia; 2012; 79(1):6-13. PubMed ID: 22344568
[TBL] [Abstract][Full Text] [Related]
17. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients.
Kay GG; Abou-Donia MB; Messer WS; Murphy DG; Tsao JW; Ouslander JG
J Am Geriatr Soc; 2005 Dec; 53(12):2195-201. PubMed ID: 16398909
[TBL] [Abstract][Full Text] [Related]
18. Are we shortchanging frail older people when it comes to the pharmacological treatment of urgency urinary incontinence?
Gibson W; Athanasopoulos A; Goldman H; Madersbacher H; Newman D; Spinks J; Wyndaele JJ; Wagg A
Int J Clin Pract; 2014 Sep; 68(9):1165-73. PubMed ID: 25196247
[TBL] [Abstract][Full Text] [Related]
19. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
Wagg A; Compion G; Fahey A; Siddiqui E
BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
[TBL] [Abstract][Full Text] [Related]
20. Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder.
Kachru N; Sura S; Chatterjee S; Aparasu RR
Drugs Aging; 2016 Oct; 33(10):755-763. PubMed ID: 27681701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
